Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Management of postmenopausal women: Collège National des Gynécologues et Obstétriciens Français (CNGOF) and Groupe d'Etude sur la Ménopause et le Vieillissement (GEMVi) Clinical Practice Guidelines

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Contributors:
      Institut des Maladies Métaboliques et Casdiovasculaires (UPS/Inserm U1297 - I2MC); Université Toulouse III - Paul Sabatier (UT3); Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM); Centre Hospitalier Universitaire de Toulouse (CHU Toulouse); Sorbonne Université (SU); CHU Tenon AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU); Maternité Port-Royal CHU Cochin; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin AP-HP; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Obstetrical, Perinatal and Pediatric Epidemiology; Centre for Research in Epidemiology and Statistics; Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE); Centre Léon Bérard Lyon; Centre Hospitalier Lyon Sud CHU - HCL (CHLS); Hospices Civils de Lyon (HCL); Health Service and Performance Research (HESPER); Université Claude Bernard Lyon 1 (UCBL); Université de Lyon-Université de Lyon; Institut Pasteur de Lille; Pasteur Network (Réseau International des Instituts Pasteur); Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille); Unité de Nutrition Humaine (UNH); Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Clermont Auvergne (UCA); CHU Clermont-Ferrand; Hôpital Pellegrin; Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux)-Groupe hospitalier Pellegrin; Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux); CHU Montpellier = Montpellier University Hospital; Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier); Université de Montpellier (UM); Hôpital Jeanne de Flandre Lille; Hôpital Nord CHU - APHM; Institut de Cancérologie de Strasbourg Europe (ICANS); Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC); Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS); Les Hôpitaux Universitaires de Strasbourg (HUS); Nantes Université (Nantes Univ); Polyclinique de l’Atlantique; Partenaires INRAE; Institut Mère Enfant Alix de Champagne; Centre hospitalier universitaire de Poitiers = Poitiers University Hospital (CHU de Poitiers La Milétrie )
    • بيانات النشر:
      CCSD
      Elsevier
    • الموضوع:
      2022
    • Collection:
      Université de Montpellier: HAL
    • نبذة مختصرة :
      International audience ; Aim: The aim of these recommendations is to set forth an individualized approach to the management of early postmenopausal women (i.e., within the first 10 years after natural menopause) covering all aspects of lifestyle and therapeutic management, with or without menopause hormone therapy (MHT). Materials and methods: Literature review and consensus of French expert opinion. Recommendations were graded according to the HAS methodology and levels of evidence derived from the international literature, except when there was no good-quality evidence. Summary recommendations: The beginning of menopause is an ideal time for each woman to evaluate her health status by assessing her bone, cardiovascular, and cancer-related risk factors that may be amplified by postmenopausal estrogen deficiency and by reviewing her lifestyle habits. Improving lifestyle, including nutrition and physical activity, and avoiding risk factors (notably smoking), should be recommended to all women. MHT remains the most effective treatment for vasomotor symptoms but it could be also recommended as first-line treatment for the prevention of osteoporosis in early postmenopausal women at low to moderate risk for fracture. The risks of MHT differ depending on its type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used. There is reasonable evidence that using transdermal estradiol in association with micronized progesterone or dydrogesterone may limit both the venous thromboembolic risk associated with oral estrogens and the risk of breast cancer associated with synthetic progestins. Treatment should be individualized to each woman, by using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of its benefit-risk balance. For bothersome genitourinary syndrome of menopause (GSM) symptoms, vaginal treatment with lubricants and moisturizers is recommended as first-line treatment together with low-dose vaginal estrogen therapy, ...
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/35717745; PUBMED: 35717745; WOS: 000830258000001
    • الرقم المعرف:
      10.1016/j.maturitas.2022.05.008
    • الدخول الالكتروني :
      https://hal.inrae.fr/hal-03884251
      https://hal.inrae.fr/hal-03884251v1/document
      https://hal.inrae.fr/hal-03884251v1/file/Tr%C3%A9mollieres_2022.pdf
      https://doi.org/10.1016/j.maturitas.2022.05.008
    • Rights:
      http://creativecommons.org/licenses/by/ ; info:eu-repo/semantics/OpenAccess
    • الرقم المعرف:
      edsbas.EBE0BED3